BRAF and neoplasm: These approvals target distinct molecular alterations such as tumor mutational burden (TMB), mismatch repair (MMR) deficiencies, microsatellite instability (MSI) status, neurotrophic tyrosine receptor kinase gene (NTRK) fusions, rearranged during transfection (RET) fusion, and rapidly accelerated fibrosarcoma B-type (BRAF) mutations.